Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Drug Metabolism Reviews is Scopus-indexed (Q1, CiteScore 7.1), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 0360-2532Verify ISSN ↗1097-9883Verify ISSN ↗
Publisher: Taylor and Francis Ltd.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics (all) | 8 / 79 | 90th | Q1 |
| Pharmacology (medical) | 54 / 278 | 80th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1974–present (also 1972), best quartile Q1, CiteScore 7.1.
Drug Metabolism Reviews is Q1 in Pharmacology, Toxicology and Pharmaceutics (all) (rank 8 of 79) and Q1 in Pharmacology (medical) (rank 54 of 278), by CiteScore 2025.
Drug Metabolism Reviews is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 7.1, which places it in quartile Q1 at the 90th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.930, quartile Q1, with an H-index of 117.
Drug Metabolism Reviews is published by Taylor and Francis Ltd. Its print ISSN is 0360-2532 and its online ISSN is 1097-9883.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Drug Metabolism Reviews has an h-index of 145 and a 2-year mean of 4.82 citations per paper (OpenAlex). Its Scopus CiteScore is 7.1, quartile Q1. On 2-year citations it ranks #7 of 77 Scopus journals in Pharmacology, Toxicology and Pharmaceutics (all).
Drug Metabolism Reviews published 25 papers in 2025; its busiest recent year was 2019 with 33. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2022–2026), authors are most often from China (23.7%), United States (18.7%) and India (15.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.